RS58234B1 - Upotreba agensa za modifikovanje hormona adrenalina - Google Patents

Upotreba agensa za modifikovanje hormona adrenalina

Info

Publication number: RS58234B1
Authority: RS; Serbia
Prior art keywords: modifying agent; adrenal hormone; adrenal; hormone; modifying
Prior art date: 2010-01-14

Application number

RS20190043A

Other languages

English (en)

Inventor

Qi-Ying Hu

Gary Ksander

Erik Meredith

Lauren G Monovich

Julien Papillon

Christoph Schumacher

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-14

Filing date

2011-01-13

Publication date

2019-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58234(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-13 Application filed by Novartis Ag filed Critical Novartis Ag

2019-03-29 Publication of RS58234B1 publication Critical patent/RS58234B1/sr

Links

230000001919 adrenal effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RS20190043A 2010-01-14 2011-01-13 Upotreba agensa za modifikovanje hormona adrenalina RS58234B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29498010P	2010-01-14	2010-01-14
PCT/US2011/021100 WO2011088188A1 (en)	2010-01-14	2011-01-13	Use of an adrenal hormone-modifying agent
EP11702096.6A EP2523731B1 (en)	2010-01-14	2011-01-13	Use of an adrenal hormone-modifying agent

Publications (1)

Publication Number	Publication Date
RS58234B1 true RS58234B1 (sr)	2019-03-29

Family

ID=43735742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20190043A RS58234B1 (sr)	2010-01-14	2011-01-13	Upotreba agensa za modifikovanje hormona adrenalina

Country Status (33)

Country	Link
US (2)	US8609862B2 (sr)
EP (2)	EP2523731B1 (sr)
JP (4)	JP5602250B2 (sr)
KR (1)	KR101412206B1 (sr)
CN (2)	CN105440038A (sr)
AU (1)	AU2011205290C1 (sr)
BR (1)	BR112012017458B1 (sr)
CA (1)	CA2786443C (sr)
CL (1)	CL2012001961A1 (sr)
CY (2)	CY1121320T1 (sr)
DK (1)	DK2523731T3 (sr)
ES (1)	ES2707596T3 (sr)
HR (1)	HRP20190064T1 (sr)
HU (2)	HUE041967T2 (sr)
IL (1)	IL220804A0 (sr)
LT (2)	LT2523731T (sr)
LU (1)	LUC00159I2 (sr)
MA (1)	MA33904B1 (sr)
ME (1)	ME03371B (sr)
MX (2)	MX2012008212A (sr)
NL (1)	NL301043I2 (sr)
NO (1)	NO2020012I1 (sr)
NZ (1)	NZ601077A (sr)
PL (1)	PL2523731T3 (sr)
PT (1)	PT2523731T (sr)
RS (1)	RS58234B1 (sr)
RU (1)	RU2598708C2 (sr)
SG (1)	SG182393A1 (sr)
SI (1)	SI2523731T1 (sr)
TN (1)	TN2012000352A1 (sr)
TR (1)	TR201900515T4 (sr)
WO (1)	WO2011088188A1 (sr)
ZA (1)	ZA201205058B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5602250B2 (ja) *	2010-01-14	2014-10-08	ノバルティスアーゲー	副腎ホルモン修飾剤の使用
WO2011159871A2 (en)	2010-06-16	2011-12-22	Embera Neurotherapeutics, Inc	Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
TWI518073B (zh)	2011-06-14	2016-01-21	美國禮來大藥廠	醛固酮合成酶抑制劑
EP2757882B1 (en)	2011-09-22	2020-11-04	Merck Sharp & Dohme Corp.	Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en)	2011-09-22	2021-01-13	Merck Sharp & Dohme Corp.	Triazolopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en)	2011-09-22	2016-05-31	Merck Sharp & Dohme Corp.	Pyrazolopyridyl compounds as aldosterone synthase inhibitors
BR112014017260A8 (pt) *	2012-01-17	2017-07-04	Novartis Ag	formas e sais de um inibidor de di-hidropirrolo[1,2-c]imidazolil aldosterona sintase ou aromatase
IN2014DN09240A (sr) *	2012-04-12	2015-07-10	Novartis Ag
US9550750B2 (en)	2012-10-05	2017-01-24	Merck Sharp & Dohme Corp.	Indoline compounds as aldosterone synthase inhibitors
JP2015093832A (ja) *	2013-11-08	2015-05-18	日本メジフィジックス株式会社	放射性ハロゲン標識化合物又はその塩、これを含む医薬
EA201991359A1 (ru) *	2014-07-07	2020-03-13	Новартис Аг	Фармацевтические лекарственные формы
WO2016048984A1 (en) *	2014-09-25	2016-03-31	Cortendo Ab (Publ)	Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
RS61908B1 (sr) *	2015-01-29	2021-06-30	Recordati Ag	Postupak za proizvodnju kondenzovanih imidazolo derivata
US20160287565A1 (en)	2015-04-06	2016-10-06	Millendo Therapeutics, Inc.	Combination therapy for treating disorders associated with excess cortisol production
EP3310358A4 (en) *	2015-06-22	2019-08-28	Embera Neurotherapeutics, Inc.	COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE, SEARCH AND PSYCHIATRIC DISORDER
CN110582278B (zh)	2017-03-10	2023-04-18	伊姆贝拉神经疗法公司	药物组合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4889861A (en) *	1982-12-21	1989-12-26	Ciba-Geigy Corp.	Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en)	1987-07-28	1989-03-21	The Trustees Of Dartmouth College	Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) *	1994-04-22	1996-04-02	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en)	1994-10-14	1997-08-19	Twk, Inc.	Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de)	1998-03-30	1999-10-14	Lohmann Therapie Syst Lts	Feuchtigkeitsaktivierbares therapeutisches System
EP1121111B1 (en)	1998-10-15	2010-02-10	Imperial Innovations Limited	Compounds for the treatment of weight loss
JP4497814B2 (ja) *	2001-02-16	2010-07-07	アベンティス・ファーマスーティカルズ・インコーポレイテツド	新規複素環式尿素誘導体およびドーパミンｄ３受容体リガンドとしてのそれらの使用
TWI263640B (en) *	2001-12-19	2006-10-11	Bristol Myers Squibb Co	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
JP5138875B2 (ja)	2005-07-19	2013-02-06	株式会社デンソー	センサ装置
GT200600381A (es) *	2005-08-25	2007-03-28		Compuestos organicos
TW200804378A (en)	2005-12-09	2008-01-16	Speedel Experimenta Ag	Organic compounds
EP2007206A4 (en)	2006-03-16	2010-12-08	Yeda Res & Dev	METHOD AND COMPOSITION FOR THE PROTECTION OF NEURONAL TISSUE FROM DEGATES INDUCED BY HIGH LEVELS OF GLUTAMATE
AU2007267793A1 (en) *	2006-05-26	2007-12-06	Novartis Ag	Aldosterone synthase and/or 11beta-hydroxylase inhibitors
EP1886695A1 (en)	2006-06-27	2008-02-13	Speedel Experimenta AG	Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
BRPI0715938A2 (pt) *	2006-08-25	2014-05-20	Novartis Ag	Derivados de imidazol fundidos para o tratamento de distúrbios mediados por aldosterona sintase e/ou 11-beta-hidroxilase e/ou aromatase
EA200900812A1 (ru) *	2006-12-18	2009-12-30	Новартис Аг	Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы
EP2095819A1 (en)	2008-02-28	2009-09-02	Maastricht University	N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR072297A1 (es)	2008-06-27	2010-08-18	Novartis Ag	Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP5602250B2 (ja) *	2010-01-14	2014-10-08	ノバルティスアーゲー	副腎ホルモン修飾剤の使用
BR112014017260A8 (pt) *	2012-01-17	2017-07-04	Novartis Ag	formas e sais de um inibidor de di-hidropirrolo[1,2-c]imidazolil aldosterona sintase ou aromatase
IN2014DN09240A (sr) *	2012-04-12	2015-07-10	Novartis Ag

2011
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Application Filing
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en active Application Filing
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 RU RU2012134510/15A patent/RU2598708C2/ru active
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
2019
- 2019-01-09 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I1/el unknown

Also Published As

Publication number	Publication date
KR101412206B1 (ko)	2014-06-25
CN102711916A (zh)	2012-10-03
HUE041967T2 (hu)	2019-06-28
NO2020012I1 (no)	2020-06-09
RU2598708C2 (ru)	2016-09-27
US9434754B2 (en)	2016-09-06
EP2523731A1 (en)	2012-11-21
JP2013517280A (ja)	2013-05-16
KR20120116482A (ko)	2012-10-22
AU2011205290B2 (en)	2014-06-26
MX2012008212A (es)	2012-08-03
PL2523731T3 (pl)	2019-04-30
PT2523731T (pt)	2019-01-21
HUS2000018I1 (hu)	2020-07-28
US20140171392A1 (en)	2014-06-19
JP5602250B2 (ja)	2014-10-08
LTPA2020512I1 (lt)	2020-07-27
CY2020018I2 (el)	2020-11-25
CN105440038A (zh)	2016-03-30
TN2012000352A1 (en)	2014-01-30
EP2523731B1 (en)	2018-10-24
NZ601077A (en)	2014-07-25
EP3527208A1 (en)	2019-08-21
ES2707596T3 (es)	2019-04-04
DK2523731T3 (en)	2019-02-04
BR112012017458B1 (pt)	2020-10-20
IL220804A0 (en)	2012-08-30
CA2786443A1 (en)	2011-07-21
MA33904B1 (fr)	2013-01-02
LUC00159I2 (sr)	2021-07-06
RU2012134510A (ru)	2014-02-20
JP2017002063A (ja)	2017-01-05
SG182393A1 (en)	2012-08-30
JP6425688B2 (ja)	2018-11-21
CL2012001961A1 (es)	2013-03-22
SI2523731T1 (sl)	2019-02-28
NL301043I2 (nl)	2020-07-06
CY2020018I1 (el)	2020-11-25
JP2018150326A (ja)	2018-09-27
JP2015013859A (ja)	2015-01-22
JP6181610B2 (ja)	2017-08-16
NL301043I1 (nl)	2020-06-17
LT2523731T (lt)	2019-02-11
HUS000508I2 (hu)	2021-03-29
BR112012017458A2 (pt)	2017-12-19
LTC2523731I2 (lt)	2022-05-10
AU2011205290C1 (en)	2014-11-06
ME03371B (me)	2020-01-20
CA2786443C (en)	2018-12-11
US8609862B2 (en)	2013-12-17
LUC00159I1 (sr)	2020-06-16
AU2011205290A1 (en)	2012-08-02
ZA201205058B (en)	2014-04-30
TR201900515T4 (tr)	2019-02-21
US20120295888A1 (en)	2012-11-22
MX354022B (es)	2018-02-08
CY1121320T1 (el)	2020-05-29
HRP20190064T1 (hr)	2019-03-08
WO2011088188A1 (en)	2011-07-21
CN102711916B (zh)	2015-09-02

Publication	Publication Date	Title
HUS2000018I1 (hu)	2020-07-28	Mellékvese hormon-módosító szer alkalmazása
HRP20181615T1 (hr)	2018-12-14	Terapijsko sredstvo koje izaziva citotoksičnost
IL255252A0 (en)	2017-12-31	Production of pipes
IL237581B (en)	2018-11-29	Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HK1178149A1 (en)	2013-09-06	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
EP2628092A4 (en)	2016-03-30	HARDWARE AGENT FOR ONE DEVICE
EP2566328A4 (en)	2013-10-16	indazoles
ZA201206456B (en)	2013-05-29	Uses of dgati inhibitors
HK1173368A1 (en)	2013-05-16	Pigmentation-preventing or-ameliorating agent
IL224340A (en)	2015-10-29	Sanitary cause
PT2363354E (pt)	2013-03-18	Dispensador de ingrediente activo
EP2640832A4 (en)	2014-11-12	NEW ETHIOLOGICAL AGENT
GB201009603D0 (en)	2010-07-21	Anti-inflammatory agent
HK1160777A1 (en)	2012-08-17	Novel use of neohesperidoside
GB201009342D0 (en)	2010-07-21	Use of steroid compounds
HU1000688D0 (en)	2011-02-28	Use of trifluoro-phal
TWM390349U (en)	2010-10-11	Structure of door-in-door
TWM386865U (en)	2010-08-21	Residue-filtering structure of juice-extractor
GB201018597D0 (en)	2010-12-22	Inhibitors
PL391723A1 (pl)	2012-01-16	Środek zwilżający
PL391725A1 (pl)	2012-01-16	Środek zwilżający
PL392666A1 (pl)	2012-04-23	Środek gaśniczy
TWM400763U (en)	2011-04-01	Improved structure of cold-accumulating cravats
TWM388315U (en)	2010-09-11	Improved structure of hemoclip
GB201003727D0 (en)	2010-04-21	Therapeutic agent